RestructuringAug 11, 2026, 07:12 AM
Aura Biosciences Restructures, Cuts 20% Workforce, Appoints New COO
AI Summary
Aura Biosciences announced a strategic realignment to focus on ocular oncology, including a 20% workforce reduction expected to cost $2.9 million to $3.2 million. This restructuring, combined with disciplined capital allocation, is projected to extend the cash runway into the first half of 2029. The company also reported a Q2 2026 net loss of $45.6 million and appointed Susan Abu-Absi as Chief Operating Officer, Erica Kratz as Chief Regulatory and Quality Officer, and Julie Person as Chief People Officer, while several other executives departed. The NMIBC program will be deprioritized to reallocate resources.
Key Highlights
- Strategic realignment includes a 20% workforce reduction.
- Estimated restructuring costs are $2.9 million to $3.2 million.
- Cash runway extended into 1H 2029 due to restructuring and capital allocation.
- Q2 2026 net loss was $45.6 million, compared to $27.0 million in Q2 2025.
- Phase 3 CoMpass trial fully enrolled with 108 patients; topline data expected 2H 2027.
- Susan Abu-Absi appointed COO with $520,000 annual salary and 400,000 share equity award.
- NMIBC program deprioritized to focus resources on ocular oncology.
- Cash, cash equivalents, and marketable securities totaled $323.8 million as of June 30, 2026.
Price Impact
More from AURA